Members of our team had the opportunity to present a new poster abstract at NASP inSPIRE 2026, which was held from September 22-25, 2026.
CPS Authors
Casey Fitzpatrick, PharmD; Amber Skrtic, PharmD; Muhamed Miljkovic, PharmD; Sara Kissinger, PharmD; Anne Falen, PharmD
Background
-
CPS-managed health-system specialty pharmacies (HSSPs) play a critical role in supporting the monitoring of disease activity in patients with rheumatoid arthritis (RA), often leveraging patient-reported outcome measures (PROMs) such as the Routine Assessment of Patient Index Data 3 (RAPID3).
-
The Vectra test integrates concentrations of 12 serum biomarkers with select patient characteristics (i.e., age, sex, and adiposity) to generate a composite score that reflects RA disease activity and predicts risk of radiographic progression,1 providing an objective complement to PROMs and traditional clinical assessment.
-
HSSPs are well positioned to operationalize the Vectra test into existing clinical workflows as a complement to RAPID3.2
Objectives
To describe the integration of the Vectra test into routine RA clinical management within a HSSP.
-
1
Hirate S, Dirven L, Shen Y, et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxfod). 2013;52(7):1202-1207. doi:10.1093/rheumatology/kes362
-
2
Zuckerman AD, Whelchel K, Kozlicki M, et al. Health-system specialty pharmacy role and outcomes: A review of current literature. Am J Health Syst Pharm. 2022;79(21):1906-1918. doi:10.1093/ajhp/zxac212
